Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis

Japanese Journal of Antibiotics

Volumn 66, Issue 3, 2013, Pages 159-168

  Yamagishi, Yuka ^a   Hamada, Yukihiro ^a   Hagihara, Mao ^a   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; SYSTEMIC MYCOSIS;

ADULT; AGED; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; PERITONITIS;

EID: 84880530315     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. TAKESUE, Y.; S. ODA, S. FUJISHIMA, et al.: Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care. J. Infect. Chemother. 18: 515-521, 2012
2. CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
3. LOUIE, A.; G. L. DRUSANO, P. BANERJEE, et al.: Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42: 1105-1109, 1998
4. ANDES, D. & M. VAN OGTROP: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine model of disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43: 2116-2120, 1999
5. ANDES, D. & M. VAN OGTROP: In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 44: 938-942, 2000
6. ANDES, D.; T. STAMSTED & R. CONKLIN: Pharmacodynamics of amphotericine B in a neutropenic-mouse disseminated candidiasis model. Antimicrob. Agents Chemother. 45: 922-926, 2001
7. ANDES, D.; K. MARCHILLO, J. LOWTHER, et al.: In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47: 1187-1192, 2003
8. ANDES, D.; K. MARCHILLO, T. STAMSTAD, et al.: In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47: 3165-3169, 2003
9. HAGIHARA, M.; H. KASAI, T. UMEMURA, et al.: Pharmacokinetic- pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. J. Infect. Chemother. 17: 224-230, 2011
10. DENNING, D. W.; R. M. TUCKER, L. H. HANSON, et al.: Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 86: 791-800, 1989
11. KLASTERSKY, J.: Empirical antifungal therapy. Int. J. Antimicrob. Agents 23: 105-112, 2004
12. ASCIOGLU, S.; B. E. DE PAUW & J. F. MEIS: Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int. J. Antimicrob. Agents 15: 159-168, 2000
13. OREN, I,; J. M. ROWE, H. SPRECHER, et al.: A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 38: 127-134, 2006
14. BEAL, S.; L. B. SHEINER, A. BOECKMANN, et al.: NONMEM User's Guides. (1989-2009), Icon Development Solutions, Ellicott City, MD, USA, 2009
15. ETTE, E. I.: Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37: 486-495, 1997
16. Guidelines for the Diagnosis/Treatment of Deep Mycosis in 2007. Edited be the Committee for the Preparation of Gudelines regarding Deep Mycosis. Tokyo, Kyowa Kikaku, 2007
17. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA
18. SAWCHUK, R. J. & D. E. ZASKE: Pharmacokinetics of dosing regimens which use multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet. Biopharm. 4: 183-195, 1976
19. YAMAGISHI, Y.; M. TERADA, E. OHKI, et al.: Antifungal susceptibility against Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole. Jpn. J. Antibiotics 62: 415-434, 2009